Daniel H. Shevrin

6.4k total citations · 2 hit papers
78 papers, 3.9k citations indexed

About

Daniel H. Shevrin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel H. Shevrin has authored 78 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 28 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel H. Shevrin's work include Prostate Cancer Treatment and Research (47 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Daniel H. Shevrin is often cited by papers focused on Prostate Cancer Treatment and Research (47 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Daniel H. Shevrin collaborates with scholars based in United States, France and Australia. Daniel H. Shevrin's co-authors include Robert Dreicer, Maha Hussain, Christopher J. Sweeney, Michael A. Carducci, Noah M. Hahn, Robert S. DiPaola, Nicholas J. Vogelzang, Glenn Liu, Joel Picus and Manish Kohli and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Daniel H. Shevrin

73 papers receiving 3.8k citations

Hit Papers

Chemohormonal Therapy in Metastatic Hormone-Sensitive Pro... 2015 2026 2018 2022 2015 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    2015 1.8k citations Christopher J. Sweeney, Michael A. Carducci et al. profile →
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    2018 695 citations Christos E. Kyriakopoulos, Michael A. Carducci et al. Journal of Clinical Oncology profile →

Peers

Daniel H. Shevrin
Jean-Pascal Machiels Belgium
Simon Chowdhury United Kingdom
Matthew R. Smith United States
Orazio Caffo Italy
Suneel Mundle United States
F. Zattoni Italy
Victoria J. Sinibaldi United States
Amit Bahl United Kingdom
William Jacot France
Toshinari Yamashita Japan
Jean-Pascal Machiels Belgium
Daniel H. Shevrin
Citations per year, relative to Daniel H. Shevrin Daniel H. Shevrin (= 1×) peers Jean-Pascal Machiels

Countries citing papers authored by Daniel H. Shevrin

Since Specialization
Citations

This map shows the geographic impact of Daniel H. Shevrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Shevrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Shevrin more than expected).

Fields of papers citing papers by Daniel H. Shevrin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Shevrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Shevrin. The network helps show where Daniel H. Shevrin may publish in the future.

Co-authorship network of co-authors of Daniel H. Shevrin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Shevrin. A scholar is included among the top collaborators of Daniel H. Shevrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Shevrin. Daniel H. Shevrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tripathi, Archana, David F. Jarrard, Jorge A. García, et al.. (2025). Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Annals of Oncology. 36(11). 1409–1413.
2.
Cole, Suzanne, Se Eun Kim, Andrew L. Wentland, et al.. (2025). Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).. Journal of Clinical Oncology. 43(5_suppl).
3.
4.
Shevrin, Daniel H., et al.. (2021). Associations of circulating cell-free DNA (cfDNA) and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 137–137.
5.
Morris, Michael J., Yohann Loriot, Christopher J. Sweeney, et al.. (2019). Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer. 114. 107–116. 35 indexed citations
6.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
7.
Xu, Weidong, Thomas Neill, Yang� Yang, et al.. (2014). The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Therapy. 22(3). 247–256. 76 indexed citations
8.
Victorson, David, Penny S. Brucker, Rita Bode, et al.. (2013). Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urologic Oncology Seminars and Original Investigations. 32(1). 26.e25–26.e31. 2 indexed citations
9.
Ward, Jeanette, Theodore Karrison, Gurkamal Chatta, et al.. (2011). A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer and Prostatic Diseases. 15(1). 87–92. 18 indexed citations
10.
Eton, David T., Daniel H. Shevrin, Jennifer L. Beaumont, David Victorson, & David Cella. (2010). Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer. Value in Health. 13(5). 613–623. 31 indexed citations
11.
Lai, Jin‐Shei, David Cella, Kelly K. Dineen, et al.. (2005). An item bank was created to improve the measurement of cancer-related fatigue. Journal of Clinical Epidemiology. 58(2). 190–197. 67 indexed citations
12.
Chang, Chih‐Hung, David Cella, Gregory A. Masters, et al.. (2002). Real-Time Clinical Application of Quality-of-Life Assessment in Advanced Lung Cancer. Clinical Lung Cancer. 4(2). 104–109. 34 indexed citations
13.
Küçük, Ömer, Daniel H. Shevrin, Kishan J. Pandya, & Philip Bonomi. (2000). Phase II Trial of Cisplatin, Etoposide, and 5-Fluorouracil in Advanced Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology. 23(4). 371–375. 6 indexed citations
14.
Shevrin, Daniel H., Thomas E. Lad, Michael Russell Mullane, et al.. (1994). Phase II trial of 6-thioguanine in advanced renal cell carcinoma. Investigational New Drugs. 12(4). 345–346. 2 indexed citations
15.
Lee, Chung, Daniel H. Shevrin, & James M. Kozlowski. (1993). In vivo andin vitro approaches to study metastasis in human prostatic cancer. Cancer and Metastasis Reviews. 12(1). 21–28. 18 indexed citations
16.
17.
Kukreja, Subhash C., Thomas J. Rosol, Daniel H. Shevrin, et al.. (1990). Tumor Resection and Antibodies to Parathyroid Hormone-Related Protein Cause Similar Changes on Bone Histomorphometry in Hypercalcemia of Cancer*. Endocrinology. 127(1). 305–310. 38 indexed citations
18.
Barengolts, Elena, et al.. (1990). Effects of Hypercalcemia-Producing Tumor Extract and Parathyroid Hormone on Osteoclast Ultrastructure. Cells Tissues Organs. 137(2). 160–164. 3 indexed citations
19.
Shevrin, Daniel H., et al.. (1989). Patterns of metastasis by the human prostate cancer cell line PC‐3 in athymic nude mice. The Prostate. 15(2). 187–194. 43 indexed citations
20.
Kukreja, Subhash C., Daniel H. Shevrin, Peter R. Ebeling, et al.. (1988). Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors.. Journal of Clinical Investigation. 82(5). 1798–1802. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by Matthew R. Smith Breakdown of academic impact, for papers by Orazio Caffo Breakdown of academic impact, for papers by Suneel Mundle Breakdown of academic impact, for papers by F. Zattoni Breakdown of academic impact, for papers by Victoria J. Sinibaldi Breakdown of academic impact, for papers by Amit Bahl Breakdown of academic impact, for papers by William Jacot Breakdown of academic impact, for papers by Toshinari Yamashita
Rankless by CCL
2026